ABSTRACT
Chronic anemia, transfusion-associated iron deposition, and chelating agents lead to renal impairment in ß-thalassemia (ß-thal) patients. The present study aimed to determine the most reliable and practical method in assessing and predicting renal injury in ß-thal major (ß-TM) patients. Therefore, we assessed the predictive values of urine ß2-microglobulin (ß2-MG) and neutrophil gelatinase-associated lipocalin (NGAL) levels, their ratios to urine creatinine, and serum endocan level. Sixty ß-TM patients and 30 healthy controls were included. Renal functions of the patients and controls were evaluated by means of urine protein/creatinine ratio, urine ß2-MG, urine NGAL, and serum endocan level. The ß-TM and control groups were comparable in terms of the demographic characteristics. Of the ß-TM patients, 26.7% had glomerular hyperfiltration and 41.7% had proteinuria. Compared with the control group, the ß-TM group had significantly higher levels of urine protein/creatinine, urine ß2-MG, urine ß2-MG/creatinine, urine NGAL, urine NGAL/creatinine, and serum endocan. These parameters did not differ between the chelating agent subgroups in the patient group. Urine ß2-MG/creatinine and NGAL/creatinine ratios were the parameters with high specificity in predicting proteinuria. There were significant correlations of urine ß2-MG, urine NGAL, and serum endocan levels with serum ferritin concentration. Urine ß2-MG/creatinine, NGAL/creatinine, and protein/creatinine ratios were correlated with each other in the patient group. Positive correlations of urine ß2-MG, urine NGAL, and serum endocan levels with serum ferritin concentration indicated that iron deposition was associated with endothelial damage and renal injury.
Subject(s)
Biomarkers , Kidney Diseases/diagnosis , Kidney Diseases/metabolism , Lipocalin-2/metabolism , Neoplasm Proteins/metabolism , Proteoglycans/metabolism , beta 2-Microglobulin/metabolism , beta-Thalassemia/metabolism , Adolescent , Adult , Case-Control Studies , Child , Child, Preschool , Combined Modality Therapy/adverse effects , Combined Modality Therapy/methods , Disease Susceptibility , Female , Glomerular Filtration Rate , Humans , Iron Overload/diagnosis , Iron Overload/etiology , Iron Overload/metabolism , Kidney Diseases/etiology , Kidney Function Tests , Lipocalin-2/urine , Male , Middle Aged , Neoplasm Proteins/blood , Prognosis , Proteoglycans/blood , ROC Curve , Young Adult , beta 2-Microglobulin/urine , beta-Thalassemia/complications , beta-Thalassemia/therapyABSTRACT
OBJECTIVE: In this study, we aimed to detect the incidences of ototoxicity in patients with hemoglobinopathies taking deferoxamine (DFO), deferiprone, and deferasirox using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) scale to obtain more objective data. MATERIALS AND METHODS: Fifty-five transfusion-dependent patients were evaluated in this study. The NCI CTCAE scale was used to assess ototoxicity levels. The average ferritin and hemoglobin levels, the type of iron chelator, and the duration of therapy of all the patients were recorded. RESULTS: Ototoxicity was observed in 15 patients (31.9 %), all of whom were taking DFO. The median age was 19.5 (6-43) in patients without ototoxicity and 29 (16-50) in those with ototoxicity; this difference was statistically significant (p<0.05). The median ferritin and pre-tx Hb levels were 1391 ng/mL and 9.06 mg/dL, respectively, in patients with ototoxicity and 986.7 ng/mL and 9.24 mg/dL, respectively, in those without ototoxicity; these differences were not significant (p>0.05). Ototoxicity was not observed in the eight patients who used only deferasirox and deferiprone. CONCLUSION: The ototoxicity incidence with DFO at doses below 50 mg/kg/day was 27.3%. Deferiprone and deferasirox were not associated with ototoxic effects in patients taking these drugs.
Subject(s)
Ear Diseases/chemically induced , Iron Chelating Agents/adverse effects , Thalassemia/drug therapy , Adolescent , Adult , Chelation Therapy/methods , Child , Cross-Sectional Studies , Ear Diseases/diagnosis , Ear Diseases/epidemiology , Female , Humans , Incidence , Iron Chelating Agents/administration & dosage , Male , Middle Aged , Turkey/epidemiologyABSTRACT
Allergic reactions related to blood transfusion frequently occur and most of them are mild reactions such as urticaria, erythema, pruritus and flushing. More severe and life threatening allergic reactions such as anaphylactic shock rarely occur. Application of white cell reduction filters during transfusions may prevent alloimmunization, febrile nonhemolytic reactions and transmission of intracellular infectious agents. Despite their beneficial effects, white-cell reduction filters may cause allergic reactions. In this article we present three patients who had anaphylactic reactions during blood transfusion with positively charged leucocyte filters.
